These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 7695253

  • 1. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2'R,5'S-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, an agent active against human immunodeficiency virus and human hepatitis B virus.
    Frick LW, Lambe CU, St John L, Taylor LC, Nelson DJ.
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2722-9. PubMed ID: 7695253
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.
    Frick LW, St John L, Taylor LC, Painter GR, Furman PA, Liotta DC, Furfine ES, Nelson DJ.
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2285-92. PubMed ID: 8285607
    [Abstract] [Full Text] [Related]

  • 3. (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes.
    Condreay LD, Condreay JP, Jansen RW, Paff MT, Averett DR.
    Antimicrob Agents Chemother; 1996 Feb; 40(2):520-3. PubMed ID: 8834915
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.
    Schinazi RF, Boudinot FD, Ibrahim SS, Manning C, McClure HM, Liotta DC.
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2432-8. PubMed ID: 1336946
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and metabolism of 3'-azido-2',3'-dideoxy-5-methylcytidine in rhesus monkeys.
    Boudinot FD, Schinazi RF, Doshi KJ, McClure HM, Chu CK.
    Drug Metab Dispos; 1993 Nov; 21(5):855-60. PubMed ID: 7902248
    [Abstract] [Full Text] [Related]

  • 9. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.
    Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, Ostrander M, Lang SA, Muchmore E, Chou TC.
    Antimicrob Agents Chemother; 1992 Apr; 36(4):808-18. PubMed ID: 1503443
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks.
    Cullen JM, Smith SL, Davis MG, Dunn SE, Botteron C, Cecchi A, Linsey D, Linzey D, Frick L, Paff MT, Goulding A, Biron K.
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2076-82. PubMed ID: 9333028
    [Abstract] [Full Text] [Related]

  • 12. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-beta-L-glyceropent-2-enofuranosyl)cytosine.
    Chen H, Pai SB, Hurwitz SJ, Chu CK, Glazkova Y, McClure HM, Feitelson M, Schinazi RF.
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1922-8. PubMed ID: 12760868
    [Abstract] [Full Text] [Related]

  • 13. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
    Furman PA, Davis M, Liotta DC, Paff M, Frick LW, Nelson DJ, Dornsife RE, Wurster JA, Wilson LJ, Fyfe JA.
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2686-92. PubMed ID: 1336341
    [Abstract] [Full Text] [Related]

  • 14. Hplc-nmr identification of the human urinary metabolites of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analogue active against human immunodeficiency virus (HIV).
    Shockcor JP, Wurm RM, Frick LW, Sanderson PN, Farrant RD, Sweatman BC, Lindon JC.
    Xenobiotica; 1996 Feb; 26(2):189-99. PubMed ID: 8868002
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of beta-L-2',3'-dideoxy-5-fluorocytidine in rhesus monkeys.
    Martin LT, Cretton-Scott E, Schinazi RF, Zhou XJ, McClure HM, Mathe C, Gosselin G, Imbach JL, Sommadossi JP.
    Antimicrob Agents Chemother; 1999 Apr; 43(4):920-4. PubMed ID: 10103200
    [Abstract] [Full Text] [Related]

  • 16. Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats.
    Kong XB, Vidal P, Tong WP, Chiang J, Gloff CA, Chou TC.
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1472-7. PubMed ID: 1510443
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.
    Lin CC, Yeh LT, Luu T, Lourenco D, Lau JY.
    Antimicrob Agents Chemother; 2003 Apr; 47(4):1395-8. PubMed ID: 12654676
    [Abstract] [Full Text] [Related]

  • 18. The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys.
    Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S, Johns DG.
    Drug Metab Dispos; 1987 Apr; 15(5):595-601. PubMed ID: 2891473
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Disposition of SK&F L-190144 in rats and monkeys after oral, intravenous or ocular administration.
    Tang-Liu DD, Richman JB, Lin P, Selim S.
    Biopharm Drug Dispos; 1993 May; 14(4):313-24. PubMed ID: 8499582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.